Loading…
CIK 0001056807 • 6 13F filings • May 15, 2025 – Aug 14, 2026
Import this data to Google Sheets with:
=jivedata("bvf-inc-il","13f")Uses this filer's slug. Install the Jive Data add-on first; the second argument is "13f".
Past 5 quarters
| % of Portfolio | |||||
|---|---|---|---|---|---|
| 4D MOLECULAR THERAPEUTICS IN | COM | $26.8M | 0.9%Prev: 0.6% | 2,879,289 SH | Increased-1,682,000 SH |
| AC IMMUNE SA | SHS | $54.5M | 1.7%Prev: 1.5% | 19,822,436 SH | Increased |
| ALKERMES PLC | SHS | $70.7M | 2.3% | 2,000,000 SH | New |
| ANNEXON INC | COM | $48.2M | 1.5%Prev: 0.6% | 8,698,173 SH | Increased+1,698,173 SH |
| ANTERIS TECHNOLOGIES GLOBAL | COM | $16.6M | 0.5% | 3,000,000 SH | New |
| AVALO THERAPEUTICS INC | COM NEW | $24.4M | 0.8%Prev: 0.3% | 1,632,845 SH | Increased+596,166 SH |
| COMPASS THERAPEUTICS INC | COM | $41.1M | 1.3% | 7,764,842 SH | New |
| CRESCENT BIOPHARMA INC. | COM | $50.5M | 1.6% | 2,748,763 SH | New |
| CULLINAN THERAPEUTICS INC | COM | $81.7M | 2.6%Prev: 1.8% | 5,750,683 SH | Increased |
| DISC MEDICINE INC | COM | $81.4M | 2.6% | 1,272,312 SH | New |
| ELEDON PHARMACEUTICALS INC | COM | $19.4M | 0.6%Prev: 0.9% | 6,293,282 SH | Decreased |
| ENGENE HOLDINGS INC | *W EXP 10/31/202 | $2.5M | 0.1%Prev: 0.0% | 945,402 SH | Increased |
| FOGHORN THERAPEUTICS INC | COM | $27.9M | 0.9%Prev: 0.8% | 5,842,000 SH | Increased+540,000 SH |
| GH RESEARCH PLC | ORDINARY SHARES | $121.6M | 3.9%Prev: 4.0% | 8,650,158 SH | Increased-177,554 SH |
| IMAGENEBIO INC | COM | $5.6M | 0.2% | 1,110,002 SH | New |
| IMMUNIC INC | COM | $8.5M | 0.3%Prev: 0.4% | 7,652,972 SH | Decreased-1,250,000 SH |
| IMMUNOCORE HLDGS PLC | ADS | $39.0M | 1.2% | 1,294,463 SH | New |
| INVENTIVA SA | ADS | $3.8M | 0.1%Prev: 0.1% | 686,040 SH | Increased |
| INVIVYD INC | COM | $25.4M | 0.8% | 19,525,000 SH | New |
| KURA ONCOLOGY INC | COM | $68.7M | 2.2%Prev: 2.1% | 8,445,769 SH | Increased+691,640 SH |
| KYMERA THERAPEUTICS INC | COM | $458.3M | 14.6%Prev: 5.8% | 5,502,710 SH | Increased+340,909 SH |
| MIRUM PHARMACEUTICALS INC | COM | $146.4M | 4.7%Prev: 5.1% | 1,584,727 SH | Increased-1,211,786 SH |
| MOLECULAR PARTNERS AG | ADS | $5.4M | 0.2%Prev: 0.2% | 1,353,968 SH | Decreased |
| MONTE ROSA THERAPEUTICS INC | COM | $73.4M | 2.3%Prev: 1.1% | 4,460,886 SH | Increased-1,199,246 SH |
| MOONLAKE IMMUNOTHERAPEUTICS | CLASS A ORD | $298.3M | 9.5%Prev: 31.5% | 16,001,284 SH | Decreased-3,750,000 SH |
| NEKTAR THERAPEUTICS | COM NEW | $184.2M | 5.9% | 2,559,595 SH | New |
| OLEMA PHARMACEUTICALS INC | COM | $79.0M | 2.5%Prev: 0.8% | 5,295,893 SH | Increased |
| ONKURE THERAPEUTICS INC | COM CL A | $8.2M | 0.3% | 1,978,972 SH | New |
| PALVELLA THERAPEUTICS INC NE | COM | $119.8M | 3.8%Prev: 0.8% | 960,989 SH | Increased+264,434 SH |
| REVOLUTION MEDICINES INC | COM | $277.8M | 8.9%Prev: 7.2% | 2,856,782 SH | Increased-2,125,602 SH |
| SEPTERNA INC | COM | $32.5M | 1.0%Prev: 1.0% | 1,353,249 SH | Increased-3,042,875 SH |
| STOKE THERAPEUTICS INC | COM | $82.9M | 2.6% | 2,547,557 SH | New |
| STRUCTURE THERAPEUTICS INC | SPONSORED ADS | $166.7M | 5.3%Prev: 1.2% | 3,459,358 SH | Increased+1,687,941 SH |
| SUTRO BIOPHARMA INC | COM SHS | $31.2M | 1.0% | 1,251,788 SH | New |
| TENAX THERAPEUTICS INC | COM NEW | $5.4M | 0.2%Prev: 0.1% | 339,549 SH | Increased |
| TSCAN THERAPEUTICS INC | COM | $5.6M | 0.2%Prev: 0.3% | 5,564,290 SH | Decreased+674,816 SH |
| TYRA BIOSCIENCES INC | COM | $75.7M | 2.4%Prev: 1.5% | 1,976,196 SH | Increased-1,967,998 SH |
| X4 PHARMACEUTICALS INC | COM NEW | $9.2M | 0.3% | 2,233,742 SH | New |
| XENCOR INC | COM | $86.0M | 2.7%Prev: 1.2% | 7,133,720 SH | Increased+4,393,579 SH |
| XOMA ROYALTY CORPORATION | COM NEW | $81.3M | 2.6%Prev: 2.4% | 2,590,303 SH | Increased-392,723 SH |
| ZYMEWORKS INC | COM | $93.5M | 3.0%Prev: 2.1% | 3,734,142 SH | Increased-574,793 SH |
| 13F-HR |
| 0000921895-26-002163 |
| $3.91B |
| View |
| Aug 14, 2025 | Q2 2025 | 13F-HR | 0000921895-25-002281 | $2.80B | View |
| May 15, 2026 | Q1 2026 | 13F-HR | 0000921895-26-001382 | $3.14B | View |
| May 15, 2025 | Q1 2025 | 13F-HR | 0000921895-25-001528 | $2.45B | View |